A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Clinical trial NCT03225716 · TERMINATED
Trial details
- NCT number
- NCT03225716
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-20
- Primary completion
- 2022-12-31
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.